| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Fust Matthew K is a Director at RARE, with reported holdings spanning 5 companies. Recent filings cover 0 purchases and 25 sales. Those positions are worth an estimated $187K at current prices.
Our model assigns Fust Matthew K a strong insider score of 77/100, based on 12 past trades. Over a 12-month horizon, 81.8% of those trades were profitable, with an average 12-month return of +31.0%.
Fust Matthew K's largest disclosed position is in NMRA as Director, worth about $177K. The recent filings there lean toward selling, a net 21,788 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 12, 2021 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 5,000 | $20.71 | $103,550.00 | -28.5% | -5.6% | -1.9% | |
| Jul 6, 2020 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sale+OE | 6,181 | $90.00 | $556,290.00 | -31.3% | - | - | |
| Jul 1, 2020 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sale+OE | 5,000 | $85.00 | $425,000.00 | -27.0% | - | - | |
| May 18, 2020 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sell | 1,875 | $75.00 | $140,625.00 | -14.6% | - | - | |
| Apr 22, 2020 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sell | 1,875 | $65.00 | $121,875.00 | -12.7% | - | - | |
| Dec 16, 2019 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 3,500 | $22.50 | $78,750.00 | -21.8% | - | - | |
| Feb 6, 2019 | MGNX MacRogenics Inc | Director | Sale+OE | 6,924 | $29.38 | $203,427.12 | -93.3% | - | - | |
| May 30, 2018 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sell | 6,319 | $72.00 | $454,969.26 | -41.9% | - | - | |
| May 14, 2018 | ATRA Atara Biotherapeutics, Inc. | Director | Sale+OE | 12,286 | $43.57 | $535,301.02 | -38.3% | - | - |